Intellipharmaceutics International, Inc. (IPCI) is “One to Watch”

Pharmaceutical company Intellipharmaceutics International is poised for a potential landmark year.

Specializing in the research, development, and commercialization of controlled-release and targeted pharmaceutical products, Intellipharmaceutics waits at the ready with product candidates that have helped the company garner “Buy” ratings from four different analysts.

Analysts from three firms, including Ladenburg Thalmann and Maxim Group, have projected a $7 price target for Intellipharmaceutics. Jason Kolbert of Maxim Group foresees that Intellipharmaceutics can become a pioneer in launching generic long-acting versions of existing therapeutics – also cashing in on the growing concern over prescription drug abuse and recent legislative efforts to curtail that problem through the development of abuse-deterrent drugs.

Rexista is an Intellipharmaceutics drug delivery platform that has been created to work with opioids to prevent abuse of them by injection, inhalation, or oral ingestion. Users commonly abuse oxycodone, for example, by pairing it with alcohol – a combination that can be lethal. Rexista provides an answer to this abuse problem by keeping the entire dose of oxycodone or other opioid from being released when alcohol is present in the system – thus negating the effects the abuser was hoping to achieve.

In February, Rep. William Keating, D-Mass., introduced “H.R. 486: Stop Tampering of Prescription Pills Act of 2013,” a bill aimed at incentivizing the development of abuse-deterrent drugs. The FDA has additionally released recent statements about its concern over prescription opioid abuse. As the nation seeks solutions for this ever-growing problem, Intellipharmaceutics is poised to capitalize.

In addition to Rexista, Intellipharmaceutics has other pipeline products in line that promise lucrative earnings. The company’s Focalin XR, a time-release drug used in the treatment of ADHD, is awaiting FDA clearance and has the potential for first-to-file status. The market for Focalin XR is projected to be more than $614 million in the United States alone.

If analysts’ estimates are correct, Intellipharmaceutics is a company that should be watched very closely. For more information on the company, visit www.intellipharmaceutics.com.

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html